Shanghai Sci-tech Capital under SIG Accepted by S&T Innovation Board
- Recent reports
-
2023-04-28
Strengthening the Fulfillment of Responsibilities, Eliminating Potential Hazards: SIG Conducts Safety Inspection before "May Day" Holiday
Learn more
-
2023-04-27
Nearly 100 Invested Enterprises of SSC Selected into Global Unicorn Index 2023
Learn more
-
2023-04-26
Seizing Opportunity, Recording Lowest Coupon Rate, Enhancing Market Visibility: SSAM Successfully Issues First-Tranche MTNs in 2023
Learn more
On April 11, Shanghai Sci-tech Capital under Shanghai International Group (SIG) was accepted by the Science and Technology Innovation Board of the Shanghai Stock Exchange through Shanghai MicroPort Endovascular MedTech Co., Ltd. (Endovastec) funded by Shanghai Lianyi Investment Center (limited partnership).
Founded in 2012, Endovastec was registered at Shanghai International Medical Park. As a subsidiary of MicroPort Scientific Corporation (HK00853), it is committed to the R&D, manufacture and sales of aorta and peripheral vessel intervention medical devices. As one of the domestic markets with the most complete products, largest scale and strongest market competitiveness, it has been up to domestic or international leading standards in terms of core technology.
Endovastec has obtained 86 domestic and foreign patients. The project of "Key Technology Development and Massive Industrialization of Macrovascular Stent Series" involving Endovastec won the Second National Award for Science and Technology Progress in 2017, created a series of homemade macrovascular stent products up to advanced international standards, advanced the development and progress of the clinical application of domestic macrovascular disease diagnosis and treatment technology, and promoted the rise of the domestic macrovascular disease minimally invasive treatment industry chain.
